Table 2. Associations Between Intravenous Tenecteplase vs Alteplase and Prespecified Outcomes.
| Outcome | No. studies | OR (95% CI) | I2, % | P value for Cochran Q |
|---|---|---|---|---|
| Crude | ||||
| 3-mo good functional outcome (mRS 0-2) | 5a | 1.22 (0.90-1.66) | 16 | .03 |
| Successful recanalization | 4 | 2.82 (1.12-7.10) | 65 | .04 |
| Early neurologic improvement | 2 | 4.88 (2.03-11.71) | 0 | .35 |
| 3-mo excellent functional outcome (mRS 0-1) | 3 | 1.53 (0.81-2.91) | 0 | .42 |
| Symptomatic intracranial hemorrhage | 5 | 0.97 (0.44-2.16) | 15 | .32 |
| Parenchymal hematoma | 3 | 1.20 (0.24-5.95) | 26 | .26 |
| Adjusted | ||||
| 3-mo good functional outcome (mRS 0-2) | 3 | 1.60 (1.08-2.37) | 16 | .30 |
| Successful recanalization | 4 | 2.38 (1.18-4.81) | 39 | .18 |
| Early neurologic improvement | 2 | 7.60 (1.97-29.41) | 0 | .80 |
| 3-mo excellent functional outcome (mRS 0-1) | 2 | 2.51 (0.66-9.49) | 54 | .14 |
| Symptomatic intracranial hemorrhage | 2 | 1.16 (0.13-10.50) | 69 | .07 |
| Parenchymal hematoma | NA | NA | NA | NA |
Abbreviations: mRS, modified Rankin Scale; NA, not available; OR, odds ratio.
a
Data on the primary outcome of interest were not available.21